Shams Iftikhar Iqbal MD, Presenter: Nothing to Disclose

Kalpana Yeddula MBBS, Abstract Co-Author: Nothing to Disclose

Rahmi Oklu MD, Abstract Co-Author: Nothing to Disclose

Suvranu Ganguli MD, Abstract Co-Author: Research Consultant, Covidien AG

Gloria Maria Martinez Salazar MD, Abstract Co-Author: Nothing to Disclose

Thomas Gregory Walker MD, Abstract Co-Author: Nothing to Disclose

Stephan Wicky MD, Abstract Co-Author: Nothing to Disclose

Sanjeeva P. Kalva MD, Abstract Co-Author: Nothing to Disclose

To evaluate the safety and effectiveness of the "Option" inferior vena cava (IVC) filter during placement and short-term follow-up.

The “OptionTM” IVC filter (Angiotech® Pharmaceuticals Inc, Vancouver, BC) is FDA approved for use in both permanent and retrievable indications for the prevention of pulmonary emboli. The clinical data of 143 patients (83 men; age range: 19-92 years) who had a Option IVC filter implanted between July 2009 and December 2010 were reviewed. 23 patients (16%) presented with pulmonary embolism (PE), 39 (27%) with deep vein thrombosis (DVT), 17 (12%) with both, and the remainder (45%) with other symptoms. Indications for filter placement were contraindication to anticoagulation (n = 76; 53%), failure of anticoagulation (n= 6, 4%) and prophylaxis/added protection (n = 61; 43%). Filters were placed in the infrarenal (n = 139) or suprarenal (n = 4) IVC. Procedure related and follow-up data were reviewed for filter-related complications and recurrent PE

20/143 (14%) filters were implanted using intravascular ultrasound guidance, 13/143 (9%) were placed using both fluoroscopic and IVUS guidance in patinets with renal dyspunction or allergy to contrast and 110/143 (77%) using fluoroscopy . Aproach used were right jugular vein approach in 44/143 (31%), left CFV in 11/143 (8%) and right CFV in 88/143 (61%). All filters were successfully deployed. There were 3/143 (2%) groin hematoma. Immediately following filter deployment, 6/143 filters (4%) showed significant tilt of more than 15 degrees. One filter was placed in the right common iliac vein which was repositioned successfully. During clinical follow-up (median 57d, range: 6-74), no patients developed clinical symptoms of PE.  Follow-up abdominal CT, available in 38 patients, showed filter leg penetration of >3mm in 1/38 patient . 2/38 patients show filter migation. No IVC occlusion was seen. 13/143 filters were retrieved with the maximum time to retrieval was 337days. 34 patients died during the follow up, unrelated to IVC filter.

The Option IVC filter was safe during placement and short-term follow-up. There was no incidence of post-filter PE in our group.

IVC filer are mechanical devices useful for preventing pulmonary embolism. Option ivc filter is a new product and the evaluation of safety and efficacy puts the use of this filter on a firm footing.

Iqbal, S, Yeddula, K, Oklu, R, Ganguli, S, Salazar, G, Walker, T, Wicky, S, Kalva, S, "New Kid on the Block": A Safety and Efficacy Evaluation of a New Inferior Vena Cava Filter.  Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, November 26 - December 2, 2011 ,Chicago IL. http://archive.rsna.org/2011/11015177.html